Status:
TERMINATED
A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
British Columbia Centre for Disease Control
Conditions:
Genital Warts
HPV
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to examine the effect of 400 mg of oral zinc gluconate on genital warts. Our hypothesis is that there will be a 10% difference in complete clearance of genital warts in th...
Detailed Description
Clients presenting to the BCCDC STI clinic with genital warts will be randomized to either 400 mg zinc gluconate or placebo (200mg BID) for 8 weeks in addition to the standard of care. Clinical assess...
Eligibility Criteria
Inclusion
- Adults age 19 and over
- Clinical diagnosis of genital warts requiring treatment based on clinician evaluation
- Fluency in English
- Available within four days of the intended 8 week follow-up visit
Exclusion
- Individuals under the age of 19
- Pregnant women
- Known contraindication to zinc Signs of copper/iron deficiency which include anemia and neutropenia which are characterized by tiredness, fatigue and light headedness.
- Diseases that alter zinc metabolism or absorption eg. type II diabetes mellitus, Crohn's disease, chronic leg ulcers
- Clients who are currently taking zinc for therapeutic purposes or have taken zinc in the last two months for therapeutic purposes
- Clients who have received standard of care treatment for their warts in the past month
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01468636
Start Date
November 1 2011
End Date
January 1 2012
Last Update
November 2 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Centre for Disease Control
Vancouver, British Columbia, Canada, V5Z 4R4